Eli Lilly Surpasses Q1 Earnings Expectations with Strong Guidance Raise
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: Fool
- Earnings Beat: Eli Lilly reported Q1 earnings of $8.55 per share, exceeding analyst expectations of $6.97, with sales reaching $19.8 billion, reflecting a robust year-over-year growth of 56% that underscores the company's strong market position.
- Significant Profit Growth: Driven by GLP-1 drugs, Lilly's profits surged 170% year-over-year, highlighting its competitive edge in the rapidly expanding obesity drug market, despite a 13% decline in prices due to increasing competition.
- Increased Drug Shipments: Lilly's drug shipments rose by 65% year-over-year, and while revenue growth faced pressure from price declines, the overall increase in volume sets a solid foundation for future growth.
- Diversification Strategy: Lilly is actively expanding into immunology, oncology, and neuroscience, with sales growth of 160%, indicating the company's potential beyond its GLP-1 business, which will help mitigate reliance on a single product line in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 851.210
Low
950.00
Averages
1192
High
1500
Current: 851.210
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LILLY Q1 ADJUSTED EPS REACHES USD 8.55, BEATING IBES ESTIMATE OF USD 6.66
Economic Adjustments: The report indicates an adjusted earnings per share (EPS) of $8.55, reflecting a positive outlook for the company.
Comparison with Estimates: This adjusted EPS surpasses the estimated EPS of $6.66, suggesting stronger-than-expected financial performance.
See More
Eli Lilly Q1 Earnings Forecast
- Earnings Release Date: Eli Lilly & Co. is set to announce its Q1 earnings on April 30, which is highly anticipated by the market and expected to provide insights into the company's latest developments in drug research and market performance.
- Earnings Per Share Expectation: Analysts forecast that Eli Lilly's Q1 earnings per share will reach $6.79, a significant increase from $3.34 in the same period last year, indicating a robust recovery in drug sales and market demand.
- Stock Price Movement: Despite the optimistic outlook for the earnings report, Eli Lilly's stock fell by 2.6% on Wednesday, likely influenced by overall market sentiment and profit-taking by investors, reflecting short-term market uncertainties.
- Market Reaction Analysis: Analysts maintain a cautiously optimistic view on the upcoming earnings report, anticipating that strong earnings growth will provide funding for future investments and research, thereby enhancing the company's competitive position in the pharmaceutical industry.
See More
U.S. Stocks Rise, Nasdaq Hits All-Time High
- Nasdaq Milestone: The Nasdaq 100 Index reached an all-time high, buoyed by better-than-expected earnings from Alphabet and Qualcomm, with Alphabet reporting Q1 revenue of $94.57 billion, surpassing the consensus of $91.57 billion, thus driving overall market gains.
- Strong Labor Market: U.S. initial jobless claims fell to 189,000, a 57-year low, indicating a robust labor market that exceeded expectations of 212,000, further bolstering market confidence in economic recovery.
- Declining Inflation Expectations: WTI crude oil prices dropped over 1%, leading to lower inflation expectations and bond yields, with the 10-year T-note yield down 4 basis points to 4.39%, providing support for the stock market.
- Global Economic Impact: The blockade of the Strait of Hormuz due to escalating tensions with Iran could exacerbate the global energy crisis, with Goldman Sachs estimating a reduction of nearly 500 million barrels from global crude stockpiles, potentially reaching a billion barrels by June, affecting market supply-demand dynamics.
See More
Mixed Earnings Reports from Multiple Companies
- Willis Towers Watson's Weak Performance: The insurer reported only 3% organic revenue growth in Q1, falling short of the 4.8% market expectation, leading to a 12% drop in stock price, despite adjusted earnings exceeding Wall Street forecasts, indicating potential growth challenges ahead.
- Hertz Partners with Uber: Hertz's stock surged about 18% following the announcement of a partnership with Uber, where its new Oro Mobility unit will support Uber's robotaxi initiative, with services expected to launch in the San Francisco Bay area later this year, marking a strategic move into autonomous driving.
- Altria's Earnings Beat Expectations: Altria reported adjusted earnings of $1.32 per share in Q1, surpassing the $1.25 consensus estimate, resulting in a stock increase of over 5%, while reaffirming its full-year adjusted earnings guidance, showcasing stability in the tobacco sector.
- Carrier Global's Strong Results: Carrier Global's Q1 adjusted earnings reached 57 cents, exceeding the expected 51 cents, with revenue of $5.34 billion surpassing the $5.01 billion consensus, leading to an 11% stock increase, reflecting robust performance in the building and refrigeration markets.
See More
FDA Proposes Exclusion of Weight Loss Drug Ingredients
- FDA Proposal: The U.S. Food and Drug Administration (FDA) has proposed to exclude Semaglutide and Tirzepatide from the 503B bulk list, limiting the compounding capabilities of outsourcing facilities, which may impact the market supply and accessibility of these drugs.
- Insufficient Clinical Need: The FDA stated that after reviewing available data, it found no clear clinical need to allow compounding of these drugs from raw ingredients, emphasizing patient safety and medical necessity, which could lead to restrictions on the use of related medications.
- Quality and Safety Concerns: The FDA has expressed concerns regarding the quality and safety of compounded weight-loss drugs, noting that these drugs are not reviewed by the FDA, which may pose risks such as improper storage, dosing errors, and counterfeit products, thereby affecting patient health.
- Market Reaction: Following the FDA proposal, shares of Eli Lilly and Novo Nordisk rose by 9% and 5%, respectively, indicating increased market confidence in the FDA-approved drugs from these companies, while Hims & Hers and Teladoc Health saw slight declines, reflecting market concerns over compounded medications.
See More
Eli Lilly Surpasses Q1 Earnings Expectations with Strong Guidance Raise
- Earnings Beat: Eli Lilly reported Q1 earnings of $8.55 per share, exceeding analyst expectations of $6.97, with sales reaching $19.8 billion, reflecting a robust year-over-year growth of 56% that underscores the company's strong market position.
- Significant Profit Growth: Driven by GLP-1 drugs, Lilly's profits surged 170% year-over-year, highlighting its competitive edge in the rapidly expanding obesity drug market, despite a 13% decline in prices due to increasing competition.
- Increased Drug Shipments: Lilly's drug shipments rose by 65% year-over-year, and while revenue growth faced pressure from price declines, the overall increase in volume sets a solid foundation for future growth.
- Diversification Strategy: Lilly is actively expanding into immunology, oncology, and neuroscience, with sales growth of 160%, indicating the company's potential beyond its GLP-1 business, which will help mitigate reliance on a single product line in the future.
See More
LILLY Q1 ADJUSTED EPS REACHES USD 8.55, BEATING IBES ESTIMATE OF USD 6.66
Economic Adjustments: The report indicates an adjusted earnings per share (EPS) of $8.55, reflecting a positive outlook for the company.
Comparison with Estimates: This adjusted EPS surpasses the estimated EPS of $6.66, suggesting stronger-than-expected financial performance.
See More
Eli Lilly Q1 Earnings Forecast
- Earnings Release Date: Eli Lilly & Co. is set to announce its Q1 earnings on April 30, which is highly anticipated by the market and expected to provide insights into the company's latest developments in drug research and market performance.
- Earnings Per Share Expectation: Analysts forecast that Eli Lilly's Q1 earnings per share will reach $6.79, a significant increase from $3.34 in the same period last year, indicating a robust recovery in drug sales and market demand.
- Stock Price Movement: Despite the optimistic outlook for the earnings report, Eli Lilly's stock fell by 2.6% on Wednesday, likely influenced by overall market sentiment and profit-taking by investors, reflecting short-term market uncertainties.
- Market Reaction Analysis: Analysts maintain a cautiously optimistic view on the upcoming earnings report, anticipating that strong earnings growth will provide funding for future investments and research, thereby enhancing the company's competitive position in the pharmaceutical industry.
See More
U.S. Stocks Rise, Nasdaq Hits All-Time High
- Nasdaq Milestone: The Nasdaq 100 Index reached an all-time high, buoyed by better-than-expected earnings from Alphabet and Qualcomm, with Alphabet reporting Q1 revenue of $94.57 billion, surpassing the consensus of $91.57 billion, thus driving overall market gains.
- Strong Labor Market: U.S. initial jobless claims fell to 189,000, a 57-year low, indicating a robust labor market that exceeded expectations of 212,000, further bolstering market confidence in economic recovery.
- Declining Inflation Expectations: WTI crude oil prices dropped over 1%, leading to lower inflation expectations and bond yields, with the 10-year T-note yield down 4 basis points to 4.39%, providing support for the stock market.
- Global Economic Impact: The blockade of the Strait of Hormuz due to escalating tensions with Iran could exacerbate the global energy crisis, with Goldman Sachs estimating a reduction of nearly 500 million barrels from global crude stockpiles, potentially reaching a billion barrels by June, affecting market supply-demand dynamics.
See More
Mixed Earnings Reports from Multiple Companies
- Willis Towers Watson's Weak Performance: The insurer reported only 3% organic revenue growth in Q1, falling short of the 4.8% market expectation, leading to a 12% drop in stock price, despite adjusted earnings exceeding Wall Street forecasts, indicating potential growth challenges ahead.
- Hertz Partners with Uber: Hertz's stock surged about 18% following the announcement of a partnership with Uber, where its new Oro Mobility unit will support Uber's robotaxi initiative, with services expected to launch in the San Francisco Bay area later this year, marking a strategic move into autonomous driving.
- Altria's Earnings Beat Expectations: Altria reported adjusted earnings of $1.32 per share in Q1, surpassing the $1.25 consensus estimate, resulting in a stock increase of over 5%, while reaffirming its full-year adjusted earnings guidance, showcasing stability in the tobacco sector.
- Carrier Global's Strong Results: Carrier Global's Q1 adjusted earnings reached 57 cents, exceeding the expected 51 cents, with revenue of $5.34 billion surpassing the $5.01 billion consensus, leading to an 11% stock increase, reflecting robust performance in the building and refrigeration markets.
See More
FDA Proposes Exclusion of Weight Loss Drug Ingredients
- FDA Proposal: The U.S. Food and Drug Administration (FDA) has proposed to exclude Semaglutide and Tirzepatide from the 503B bulk list, limiting the compounding capabilities of outsourcing facilities, which may impact the market supply and accessibility of these drugs.
- Insufficient Clinical Need: The FDA stated that after reviewing available data, it found no clear clinical need to allow compounding of these drugs from raw ingredients, emphasizing patient safety and medical necessity, which could lead to restrictions on the use of related medications.
- Quality and Safety Concerns: The FDA has expressed concerns regarding the quality and safety of compounded weight-loss drugs, noting that these drugs are not reviewed by the FDA, which may pose risks such as improper storage, dosing errors, and counterfeit products, thereby affecting patient health.
- Market Reaction: Following the FDA proposal, shares of Eli Lilly and Novo Nordisk rose by 9% and 5%, respectively, indicating increased market confidence in the FDA-approved drugs from these companies, while Hims & Hers and Teladoc Health saw slight declines, reflecting market concerns over compounded medications.
See More
Eli Lilly Surpasses Q1 Earnings Expectations with Strong Guidance Raise
- Earnings Beat: Eli Lilly reported Q1 earnings of $8.55 per share, exceeding analyst expectations of $6.97, with sales reaching $19.8 billion, reflecting a robust year-over-year growth of 56% that underscores the company's strong market position.
- Significant Profit Growth: Driven by GLP-1 drugs, Lilly's profits surged 170% year-over-year, highlighting its competitive edge in the rapidly expanding obesity drug market, despite a 13% decline in prices due to increasing competition.
- Increased Drug Shipments: Lilly's drug shipments rose by 65% year-over-year, and while revenue growth faced pressure from price declines, the overall increase in volume sets a solid foundation for future growth.
- Diversification Strategy: Lilly is actively expanding into immunology, oncology, and neuroscience, with sales growth of 160%, indicating the company's potential beyond its GLP-1 business, which will help mitigate reliance on a single product line in the future.
See More
